

Disclosures

Personal Commercial (15)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
AbbVie, Inc.	Research/Research Grants ‡ Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study	Significant (>= \$5,000)	General Cardiology
Alnylam	Consultant Fees/Honoraria	Significant (>= \$5,000)	Other
Amgen Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Besins	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Brainstorm Cell	Consultant Fees/Honoraria	None (\$0)	Other
CSL Behring	Research/Research Grants	Significant (>= \$5,000)	Invasive CV Angio and Interventions General Cardiology
Eli Lilly and Company	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Esperion	Research/Research Grants ‡ CLEAR Outcomes - Effects of Bempedoic Acid (ETC 1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at high risk for, Cardiovascular Disease who are Statin Intolerant	Significant (>= \$5,000)	Prevention
i20	Consultant Fees/Honoraria	Significant (>= \$5,000)	Other
Medscape	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
Medtronic	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
Novartis	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
Novo Nordisk	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
ReCor	Consultant Fees/Honoraria	Significant (>= \$5,000)	Invasive CV Angio and Interventions
v-wave	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 8/28/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 8/28/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 8/28/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.